SCHEMBL2767147

SCHEMBL2767147

CCC(CC)NC(=O)N1CCCC[C@H]1C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MME P08473 1/20 0.48
MMEL1 Q495T6 1/20 0.48
ACE P12821 6/20 0.46
REN P00797 4/20 0.46
LMNA P02545 2/20 0.46
HSD17B10 Q99714 2/20 0.46
KDM4E B2RXH2 1/20 0.46
F2 P00734 1/20 0.46
LTA4H P09960 1/20 0.46
MAPT P10636 1/20 0.46
PEPD P12955 1/20 0.46
ALOX15 P16050 1/20 0.46
PTGS1 P23219 1/20 0.46
HTR2A P28223 1/20 0.46
PTGS2 P35354 1/20 0.46
HRH1 P35367 1/20 0.46
THPO P40225 1/20 0.46
PMP22 Q01453 1/20 0.46
ACE2 Q9BYF1 1/20 0.46
RAB9A P51151 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8899040 1.00 MME (0.48) MMEMMEL1ACERENLMNA
SCHEMBL5134719 0.80 ACE (0.57) MMEMMEL1ACERENLMNA
SCHEMBL3600173 0.80 ACE (0.57) MMEMMEL1ACERENLMNA
SCHEMBL2422744 0.80 ACE (0.48) ACERENLMNAHSD17B10KDM4E
SCHEMBL2422749 0.80 ACE (0.48) ACERENLMNAHSD17B10KDM4E
SCHEMBL18676315 0.75 ITGB3 (0.54) ACERENLMNAHSD17B10KDM4E
SCHEMBL3966373 0.75 ITGB3 (0.54) ACERENLMNAHSD17B10KDM4E
SCHEMBL25285793 0.75 ACE (0.68) ACERENLMNAHSD17B10KDM4E
SCHEMBL5860164 0.75 ACE (0.49) ACERENLMNAHSD17B10KDM4E
SCHEMBL1840265 0.75 ACE (0.49) ACERENLMNAHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436183-B2 Synthetic multimerizing agents ARIAD PHARMACEUTICALS, INC. (US) 2013-05-07 US disclosed
US-20120130076-A1 Synthetic Multimerizing Agents ARIAD PHARMACEUTICALS, INC. (US) 2012-05-24 US disclosed
EP-0888303-B1 SYNTHETIC DERIVATIVES OF RAPAMYCIN AS MULTIMERIZING AGENTS FOR CHIMERIC PROTEINS WITH IMMUNOPHILIN-DERIVED DOMAINS ARIAD PHARMA INC (US) 2010-04-21 EP disclosed
US-20040006233-A1 Synthetic multimerizing agents ARIAD PHARMACEUTICALS, INC. 2004-01-08 US disclosed
US-6150527-A Synthetic multimerizing agents ARIAD PHARMACEUTICALS, INC. (US) 2000-11-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120130076-A1 Synthetic Multimerizing Agents FKBP1B, FKBP2, FKBP14 MME 218/4885MMEL1 340/4885ACE 3339/4885
US-20040006233-A1 Synthetic multimerizing agents FKBP1B, FKBP2, FKBP14 MME 200/4885MMEL1 308/4885ACE 3269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.